Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial.

C, Louvet; R, Labianca; P, Hammel; G, Lledo; MG, Zampino; T, André; A, Zaniboni; M, Ducreux; E, Aitini; J, Taïeb; R, Faroux; C, Lepere; Gramont A, de

doi:10.1200/jco.2005.06.023

Public

Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial.

Shared by NobleBlocks on May 1, 2005 • 12:00 AM UTC

Authors:

Louvet C

Labianca R

Hammel P

Abstract

<h4>Purpose</h4>Gemcitabine (Gem) is the standard treatment for advanced pancreatic cancer. Given the promising phase II results obtained with the Gem-oxaliplatin (GemOx) combination, we conducted a phase III study comparing GemOx with Gem alone in advanced pancreatic cancer.<h4>Patients and methods...

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!